Our expert scientists. Your custom assay.

Understanding how to use Oligodendrocyte Precursor Cells (OPCs) to enhance remyelination in multiple sclerosis is key to bringing new treatments to the clinic.

At Aquila, we offer screening using OPCs. By assessing the effect of your drug candidate on OPC proliferation, differentiation and apoptosis, we can help you identify compounds with the potential to enhance myelination, bringing you on the best route to the clinic.

We are also developing a high-throughput 3D OPC culture assay and hope to offer human OPC assays in the near future.

Please get in touch for further information.

How our OPC assay works

  • Mixed glial cultures are prepared and incubated according to protocol
  • OPCs are isolated and cultured with test compounds
  • Proliferation and apoptosis/toxicity readouts are assessed after 24 hours and differentiation after 7 days of treatment
  • High-resolution immunohistochemistry, combined with semi-automated image analysis techniques, allows accurate quantification of compound effects on OPCs
Contact